AWM
ITCI

Apollon Wealth Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Apollon Wealth Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,671
Closed -$484K – 1338
2025
Q1 		$484K Buy
+3,671
New +$457K 0.01% 764

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Apollon Wealth Management's ITCI Position: Q2 2025 in Review

Apollon Wealth Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,671 shares — an estimated $484K sold.

Apollon Wealth Management first reported a position in ITCI in Q1 2025 and held it in 1 quarter. The position peaked at $484K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Apollon Wealth Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Apollon Wealth Management sold 3,671 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $484K.
  • Apollon Wealth Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2025 and held it in 1 quarter.
  • Apollon Wealth Management's Intra-Cellular Therapies Inc. position peaked at $484K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Apollon Wealth Management's 13F filing for Q2 2025, filed 25 Jul 2025.